Skip to main
ATAI
ATAI logo

ATAI Stock Forecast & Price Target

ATAI Analyst Ratings

Based on 17 analyst ratings
Strong Buy
Strong Buy 71%
Buy 24%
Hold 6%
Sell 0%
Strong Sell 0%

Bulls say

ATAI Life Sciences NV demonstrates a positive outlook due to its innovative pipeline addressing mental health challenges, particularly with BPL-003 showing potential for durable effects in alcohol use disorder (AUD) and significant reductions in depression symptoms with ELE-101. The early results from clinical trials indicate robust efficacy, with notable improvements in patient outcomes, such as a 12-week period of abstinence for a significant portion of participants. Additionally, the well-tolerated nature of BPL-003 enhances its potential market opportunity and bolsters confidence in future advancements within the company's developer-focused pipeline.

Bears say

ATAI Life Sciences NV faces a negative outlook due to its high burn rate and significant cash balance depletion, which raises concerns about its financial sustainability amidst a lengthy clinical development timeline for its psychedelic-based therapies. Additionally, the company's reliance on securing further funding to support its research initiatives contributes to uncertainties regarding its operational stability. Lastly, competitive pressures in the biopharmaceutical sector, coupled with potential regulatory challenges for psychedelic medicine, may hinder ATAI’s ability to successfully translate its innovative concepts into commercially viable products.

ATAI has been analyzed by 17 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 24% recommend Buy, 6% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Atai Life Sciences BV and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Atai Life Sciences BV (ATAI) Forecast

Analysts have given ATAI a Strong Buy based on their latest research and market trends.

According to 17 analysts, ATAI has a Strong Buy consensus rating as of Jul 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.76, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.76, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Atai Life Sciences BV (ATAI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.